Analysis of macula dystrophy classifications

Video
Conference|EURETINA

Prof Carel B. Hoyng discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

Prof Carel B. Hoyng, of the Radboud University Medical Center, Department Ophthalmology, Nijmegen, The Netherlands, discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

See more EURETINA coverage

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Dr Ali Erginay discusses his EURETINA presentation
Varun Chaudhary speaks with David Hutton about the 2023 EURETINA congress
Kasperi Kankare at the iCare booth at ESCRS
Colman Cawe, director of fundraising and communications, Orbis UK
Related Content
Marco A. Zarbin, MD, PhD, Professor of Ophthalmology, Rutgers New Jersey Medical School

AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials

November 24th 2023
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

Documents indicate a corporation filing for bankruptcy. Image credit: ©Minerva Studio – stock.adobe.com

Oxurion NV will file for bankruptcy following KALAHARI data release

November 20th 2023
Article

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint

Intraoperative fluorescein angiography with fluorescein mode, patient with pars planitis with peripheral leakage.

The future is now: Innovations in vitreoretinal surgery 3D viewing systems and robotics

November 16th 2023
Article

Developing technology may offer marked improvements in surgical precision

EMA recommends approval of high-dose intravitreal aflibercept (Eylea®) 8mg for nAMD and macular oedema

EMA recommends approval of high-dose intravitreal aflibercept (Eylea®) 8mg for nAMD and macular oedema

November 13th 2023
Article

The endorsement follows FDA approval in the United States this summer

Successful treatment of bilateral diffuse uveal melanocytic proliferation with plasmapheresis

Successful treatment of bilateral diffuse uveal melanocytic proliferation with plasmapheresis

November 10th 2023
Article

In this case study, a patient with recently diagnosed cancer demonstrated significant improvement for ocular symptoms of BDUMP following plasmapheresis

AAO 2023: Advancements in dry age-related macular degeneration treatment

AAO 2023: Advancements in dry age-related macular degeneration treatment

November 6th 2023
Article

Peter K. Kaiser, MD, provides an overview of innovative therapies in development for patients with dry age-related macular degeneration.

© 2023 MJH Life Sciences

All rights reserved.